Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infectious Disease Medicine | 3 | 2020 | 3 | 1.400 |
Why?
|
| Neisseriaceae Infections | 1 | 2019 | 2 | 0.670 |
Why?
|
| Complement Inactivating Agents | 1 | 2019 | 12 | 0.670 |
Why?
|
| Health Care Costs | 2 | 2019 | 204 | 0.650 |
Why?
|
| Communicable Diseases | 5 | 2023 | 82 | 0.620 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 220 | 0.570 |
Why?
|
| Infection Control | 3 | 2019 | 96 | 0.530 |
Why?
|
| Physician's Role | 1 | 2017 | 119 | 0.530 |
Why?
|
| Physicians | 2 | 2020 | 436 | 0.520 |
Why?
|
| Referral and Consultation | 2 | 2017 | 409 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2019 | 420 | 0.470 |
Why?
|
| Cross Infection | 3 | 2013 | 151 | 0.430 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 421 | 0.430 |
Why?
|
| Veterans | 1 | 2017 | 723 | 0.320 |
Why?
|
| Specialization | 1 | 2008 | 73 | 0.300 |
Why?
|
| Ritonavir | 2 | 2023 | 14 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 724 | 0.240 |
Why?
|
| Health Personnel | 1 | 2008 | 341 | 0.240 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 86 | 0.220 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 100 | 0.190 |
Why?
|
| Encephalitis Virus, California | 1 | 2020 | 1 | 0.180 |
Why?
|
| Ochlerotatus | 1 | 2020 | 1 | 0.180 |
Why?
|
| Culicidae | 1 | 2020 | 8 | 0.180 |
Why?
|
| Meningitis | 1 | 2020 | 18 | 0.180 |
Why?
|
| Encephalitis | 1 | 2020 | 32 | 0.180 |
Why?
|
| Humans | 16 | 2023 | 59520 | 0.180 |
Why?
|
| Health Planning | 1 | 2019 | 30 | 0.170 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2019 | 4 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2019 | 38 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2015 | 5 | 0.130 |
Why?
|
| Flavivirus | 1 | 2015 | 8 | 0.130 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2015 | 6 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 376 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2019 | 479 | 0.120 |
Why?
|
| United States | 5 | 2020 | 7514 | 0.120 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 34 | 0.110 |
Why?
|
| Feces | 1 | 2014 | 96 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 95 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6011 | 0.110 |
Why?
|
| Pandemics | 3 | 2023 | 608 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 2442 | 0.100 |
Why?
|
| Microbiota | 1 | 2014 | 106 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5183 | 0.080 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 67 | 0.080 |
Why?
|
| Male | 5 | 2020 | 27574 | 0.070 |
Why?
|
| Female | 5 | 2020 | 30920 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 1281 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2004 | 188 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2004 | 51 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 282 | 0.060 |
Why?
|
| Adult | 4 | 2020 | 15789 | 0.050 |
Why?
|
| Massachusetts | 2 | 2020 | 2089 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 115 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 294 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 180 | 0.050 |
Why?
|
| Disease Vectors | 1 | 2020 | 7 | 0.050 |
Why?
|
| Mosquito Vectors | 1 | 2020 | 11 | 0.050 |
Why?
|
| Aged | 4 | 2020 | 13342 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 5089 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 121 | 0.040 |
Why?
|
| Health Priorities | 1 | 2019 | 22 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 29 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 332 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 16277 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 266 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 161 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 160 | 0.040 |
Why?
|
| Meningitis, Bacterial | 1 | 2015 | 5 | 0.030 |
Why?
|
| Acyclovir | 1 | 2015 | 20 | 0.030 |
Why?
|
| New Hampshire | 1 | 2015 | 42 | 0.030 |
Why?
|
| Ixodes | 1 | 2015 | 30 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 130 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 5017 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 308 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 314 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 553 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 19661 | 0.020 |
Why?
|
| Prospective Payment System | 1 | 2009 | 8 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 771 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2009 | 88 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2592 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4332 | 0.020 |
Why?
|
| Child | 1 | 2014 | 4306 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 5932 | 0.010 |
Why?
|